Загрузка...
Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis
BACKGROUND: Ipilimumab is a fully human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 , a key negative regulator of T-cell activation approved by the Food and Drug Administration as of March 2011 for the treatment of metastatic melanoma. As a result of the up-regulation of th...
Сохранить в:
| Опубликовано в: : | BMC Cancer |
|---|---|
| Главные авторы: | , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4350587/ https://ncbi.nlm.nih.gov/pubmed/25885696 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1074-7 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|